Evidence map›Paper›PMID 28111255›Full record

ArticleInternational journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience2017

Delayed treatment of 6-Bromoindirubin-3'-oxime stimulates neurogenesis and functional recovery after focal ischemic stroke in mice.

Li-Li Wang, Jimei Li, Xiaohuan Gu, Ling Wei, Shan Ping Yu

Open access · greenAbstract read
In one paragraph

Article in International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Neurogenesis After Stroke: A Therapeutic Perspective.Translational stroke research · 2021
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Neural regeneration research · 2018
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Li-Li WangDepartment of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Department of Anesthesiology, Emory University, School of Medicine, Atlanta, GA, USA.
Jimei LiDepartment of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Xiaohuan GuDepartment of Anesthesiology, Emory University, School of Medicine, Atlanta, GA, USA.
Ling WeiDepartment of Anesthesiology, Emory University, School of Medicine, Atlanta, GA, USA; Department of Neurology, Emory University, School of Medicine, Atlanta, GA, USA.
Shan Ping YuDepartment of Anesthesiology, Emory University, School of Medicine, Atlanta, GA, USA. Electronic address: spyu@emory.edu.
Emory University · USBeijing Friendship Hospital · CN

Funding

Stroke Treatment by Chemically-induced HypothermiaR44NS073378 · NINDS · JT PHARMACEUTICALS, INC. · PI DIX, THOMAS A., YU, SHAN P. · 2017 to 2019
$2.9M
MUSC FACIL EXPANSION &RENOV: SLE C06RR015455 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND, JOHN R · 2002 to 2002
$2.0M
Application of optogenetics in iPS cell transplantation therapy for ischemic stroR01NS085568 · NINDS · EMORY UNIVERSITY · PI GROSS, ROBERT E, WEI, LING · 2014 to 2018
$1.7M
Stroke Treatment by Chemically-induced HypothermiaR42NS073378 · NINDS · JT PHARMACEUTICALS, INC. · PI DIX, THOMAS A., YU, SHAN P. · 2015 to 2016
$1.5M
Stroke Treatment by Chemically-Induced HypothermiaR41NS073378 · NINDS · HALIMED PHARMACEUTICALS, INC. · PI DIX, THOMAS A., YU, SHAN P. · 2011 to 2012
$884k
Protection of the Brain by Chemical HypothermiaI01RX000666 · VA · VETERANS HEALTH ADMINISTRATION · PI YU, SHAN P. · 2015 to 2016
–
NCRR NIH HHS C06 RR015455NINDS NIH HHS R01 NS085568NINDS NIH HHS R41 NS073378NINDS NIH HHS R42 NS073378NINDS NIH HHS R44 NS073378RRD VA I01 RX000666
6 · The paper itself

Abstract

Glycogen synthase kinase 3β (GSK3β) was originally identified as a regulator for glycogen metabolism and is now an important therapeutic target for a variety of brain disorders including neurodegenerative diseases due to it's pivotal role in cellular metabolism, proliferation and differentiation. In the development of stroke therapies focusing on tissue repair and functional recovery, promoting neurogenesis is a main approach in regenerative medicine. In the present investigation, we explored the effects of a GSK3β specific inhibitor, 6-Bromoindirubin-3'-oxime (BIO), on regenerative activities of neuroblasts in the subventricular zone (SVZ) and functional recovery after focal cerebral ischemia. Adult C57/BL mice were subjected to occlusion of distal branches of middle cerebral artery (MCA) supplying the sensorimotor barrel cortex. Three days later, BIO (8.5μg/kg, i.p.) was administered every 2days until sacrificed at 14 or 21days after stroke. The BIO treatment significantly increased generation of neuroblasts labeled with BrdU and BrdU/doublecortin (DCX) in the SVZ. Comparing to vehicle controls, increased number of neuroblasts migrated to the peri-infarct region where they differentiate into mature neurons. Along with the elevated BDNF expression at the peri-infarct area, the number of newly formed neurons was significantly increased. BIO treatment significantly enhanced sensorimotor functional recovery after the focal ischemia. It is suggested that the GSK3 signaling may be a potential therapeutic target for regenerative treatment after ischemic stroke.

Indexed as

AnimalsBrain IschemiaBromodeoxyuridineCell CountDisease Models, AnimalDoublecortin Domain ProteinsDoublecortin ProteinEnzyme InhibitorsGlycogen Synthase Kinase 3 betaIndolesLateral VentriclesMaleMiceMice, Inbred C57BLMicrotubule-Associated ProteinsNervous System Diseases6-bromoindirubin-3'-oximeBromodeoxyuridineDcx protein, mouseDoublecortin Domain ProteinsDoublecortin ProteinEnzyme InhibitorsGlycogen Synthase Kinase 3 betaIndolesMicrotubule-Associated ProteinsNeuropeptidesOximesPhosphopyruvate Hydratase6-Bromoindirubin-3′-oxime (BIO)Cerebral ischemiaFunctional recoveryGSK3β inhibitorRegenerationWnt

Identifiers

PMID28111255
PMCPMC5344848
OpenAlexW2572957823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.